IL309160A - Subcutaneous formulation and methods for the treatment of edema resistant to oral diuretics - Google Patents

Subcutaneous formulation and methods for the treatment of edema resistant to oral diuretics

Info

Publication number
IL309160A
IL309160A IL309160A IL30916023A IL309160A IL 309160 A IL309160 A IL 309160A IL 309160 A IL309160 A IL 309160A IL 30916023 A IL30916023 A IL 30916023A IL 309160 A IL309160 A IL 309160A
Authority
IL
Israel
Prior art keywords
methods
treating edema
subcutaneous formulation
oral diuretics
refractory
Prior art date
Application number
IL309160A
Other languages
English (en)
Hebrew (he)
Original Assignee
RESQ Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RESQ Pharmaceuticals LLC filed Critical RESQ Pharmaceuticals LLC
Publication of IL309160A publication Critical patent/IL309160A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
IL309160A 2021-06-09 2022-06-09 Subcutaneous formulation and methods for the treatment of edema resistant to oral diuretics IL309160A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163208863P 2021-06-09 2021-06-09
PCT/US2022/032862 WO2022261344A1 (en) 2021-06-09 2022-06-09 Subcutaneous formulation and methods for treating edema refractory to oral diuretics

Publications (1)

Publication Number Publication Date
IL309160A true IL309160A (en) 2024-02-01

Family

ID=84425561

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309160A IL309160A (en) 2021-06-09 2022-06-09 Subcutaneous formulation and methods for the treatment of edema resistant to oral diuretics

Country Status (10)

Country Link
US (1) US20240285566A1 (cg-RX-API-DMAC10.html)
EP (1) EP4351554A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024520788A (cg-RX-API-DMAC10.html)
KR (1) KR20240042402A (cg-RX-API-DMAC10.html)
CN (1) CN117915905A (cg-RX-API-DMAC10.html)
AU (1) AU2022289724A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023025880A2 (cg-RX-API-DMAC10.html)
CA (1) CA3221710A1 (cg-RX-API-DMAC10.html)
IL (1) IL309160A (cg-RX-API-DMAC10.html)
WO (1) WO2022261344A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3160278A1 (en) 2019-12-04 2021-06-10 Balasingam Radhakrishnan Methods and compositions for treating edema refractory to oral diuretics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
WO2007149283A2 (en) * 2006-06-16 2007-12-27 Novacardia, Inc. Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
EP2086329B1 (en) * 2006-10-26 2014-07-23 The Arizona Board of Regents on behalf of the University of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
US20140128469A1 (en) * 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
CN105431145B (zh) * 2013-04-05 2019-12-10 Sc医药品有限公司 用于呋塞米的皮下施用的药物制剂
WO2019193161A1 (en) * 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
CA3160278A1 (en) * 2019-12-04 2021-06-10 Balasingam Radhakrishnan Methods and compositions for treating edema refractory to oral diuretics

Also Published As

Publication number Publication date
EP4351554A4 (en) 2025-05-07
KR20240042402A (ko) 2024-04-02
JP2024520788A (ja) 2024-05-24
US20240285566A1 (en) 2024-08-29
AU2022289724A1 (en) 2024-01-18
EP4351554A1 (en) 2024-04-17
CA3221710A1 (en) 2022-12-15
WO2022261344A8 (en) 2023-02-02
WO2022261344A1 (en) 2022-12-15
CN117915905A (zh) 2024-04-19
BR112023025880A2 (pt) 2024-02-27

Similar Documents

Publication Publication Date Title
EP4069222A4 (en) METHODS AND COMPOSITIONS FOR TREATING EDEMA NOT RESPONSIVE TO ORAL DIURETICS
AU2018243463A8 (en) 11,13-modified saxitoxins for the treatment of pain
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
MX386613B (es) El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto.
MX2016005532A (es) Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades.
NZ718825A (en) Uses of a compound of formula i for treating cancer in a subject
NZ726366A (en) Syk inhibitors
ES3065184T3 (en) Use of migalastat for treating fabry disease in pregnant patients
PH12017500933A1 (en) Sublingual administration of riluzole
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
PH12017500934B1 (en) Sublingual formulation of riluzole
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
IL267958A (en) An injectable preparation that can be used to treat heart diseases and contains fibroblasts, and a method for producing fibroblasts for medical use
NZ735952A (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
MX359770B (es) Terapia de combinacion de un inhibidor de mek e inhibidor de igf1r.
MX2021010286A (es) Formas de dosificacion de la hormona del crecimiento de accion prolongada con eficacia superior a la somatropina diaria.
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
SG10201811203TA (en) Protocols for treatment of major depressive disorder (mdd)
MX2024009649A (es) Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
MX2019004804A (es) Tratamiento para el prurigo nodula.
HK40110450A (en) Subcutaneous formulation and methods for treating edema refractory to oral diuretics
WO2019179823A8 (en) Lactobacillus fermentum for treating fructose-related diseases
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
EP4351554A4 (en) Subcutaneous formulation and methods for treating edema refractory to oral diuretics
SG10201809280PA (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders